Stat

AUH-6-96 is a potent JAK/STAT signaling inhibitor that effectively reduces Unpaired-induced transcriptional activity in Drosophila cells and inhibits tyrosine phosphorylation of STAT92E. It also suppresses both constitutive and IL-6-induced phosphorylation of STAT3 while decreasing levels of tyrosine-phosphorylated JAK3. Furthermore, AUH-6-96 induces apoptosis in cancer cells by downregulating anti-apoptotic genes downstream of STAT3, selectively reducing the viability of cancer cells with dysregulated JAK/STAT signaling. This compound is relevant for research pertaining to Hodgkin's lymphoma, breast cancer, and prostate cancer.

STAT3-IN-33 is a selective STAT3 inhibitor that demonstrates significant anti-cancer properties. It effectively inhibits cell proliferation in HCT116, MCF-7, and MDA-MB-231 cancer cell lines, with IC50 values of 6.44, 3.29, and 4.86 μM, respectively. This compound is valuable for research focused on the therapeutic applications of STAT3 inhibition in breast and colon cancer.

STAT3-IN-30 is a selective inhibitor of Signal Transducer and Activator of Transcription 3 (STAT3) with an EC50 of 13.8 μM. This compound effectively impairs STAT3-mediated signaling pathways, thereby influencing cell proliferation and survival. STAT3-IN-30 is suitable for research applications focused on cancer biology, immune response, and chronic inflammatory disorders, providing valuable insights into therapeutic targets involving STAT3 dysregulation.

inS3-54-A26 is a selective inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3) pathway. It exhibits cytotoxicity in non-cancerous lung fibroblasts with an IC50 of 4.0 μM. This compound is valuable for research applications in cancer biology and therapeutic development, particularly for exploring STAT3's role in oncogenesis and its potential as a target for anti-cancer strategies.

STAT3-IN-15 is a selective inhibitor of STAT3, a transcription factor implicated in various pathological conditions, including idiopathic pulmonary fibrosis (IPF). This compound effectively inhibits STAT3 phosphorylation, leading to a reduction in migration and deformation of epithelial cells stimulated by TGF-β1. Additionally, STAT3-IN-15 demonstrates the ability to hinder epithelial-mesenchymal transition (EMT), making it a valuable tool for research in fibrosis and related cellular processes.

Pulchinenoside E2 is a triterpene saponin that functions as a STAT3 inhibitor. It exhibits dual activity by inhibiting STAT3 and autophagy, demonstrating cytotoxic effects on HL-60 cells with an IC50 value of 2.6 µg/mL. This compound is valuable for research applications focused on cancer biology and the modulation of signaling pathways involved in cell proliferation and survival.

XZH-5 is a STAT phosphorylation inhibitor that specifically targets the phosphorylation of STAT3. This compound induces apoptosis in various cancer cell lines and significantly reduces their colony-forming ability. It serves as a valuable tool for researchers investigating the role of STAT3 in tumorigenesis and potential therapeutic strategies for cancer treatment.

PMMB-187 is a selective inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3), showing an IC50 value of 1.81 μM in MDA-MB-231 breast cancer cells. This compound effectively induces apoptosis by disrupting STAT3's transcriptional activity and nuclear localization, leading to a decrease in downstream gene expression. Additionally, PMMB-187 diminishes mitochondrial membrane potential, increases reactive oxygen species (ROS) production, and upregulates apoptosis-related protein levels. Its unique mechanism positions PMMB-187 as a valuable tool in cancer research applications.

Phenylpyropene C is a JAK/STAT pathway inhibitor known to effectively inhibit interferon-gamma (IFN-γ) mediated expression of reporter genes, with an IC50 range of 5.4 to 10.8 μM. Additionally, it serves as an inhibitor of acyl-CoA, exhibiting an IC50 of 16.0 μM. This compound is valuable for research applications focusing on the modulation of immune responses and the exploration of cytokine signaling pathways.

DM245 is an EPAC1 activator and STAT3 phosphorylation inhibitor. It effectively increases Rap1-GTP levels through selective activation of EPAC1, without affecting EPAC2 or PKA. DM245 mitigates IL-6/IL-6Rα-mediated STAT3 phosphorylation in endothelial cells and inhibits the TGF-β1-induced transition of fibroblasts to myofibroblasts, leading to decreased levels of αSMA and Collagen I. Importantly, DM245 shows minimal cytotoxicity in normal human lung fibroblasts, indicating a high safety profile for extended exposure.

YN11 is a selective inhibitor of Signal Transducer and Activator of Transcription 3 (STAT3) with a Kd of 11.9 μM. By directly binding to the SH2 domain, YN11 effectively inhibits the phosphorylation of STAT3, leading to decreased expression of downstream target proteins. This compound has demonstrated significant biological activity, inducing cell cycle arrest and promoting apoptosis in prostate cancer cells, while also inhibiting cell invasion and migration. In vivo studies indicate that YN11 suppresses tumor growth in prostate cancer xenograft models without causing significant body weight loss or histopathological changes in major organs, making it a valuable tool for research in prostate cancer therapy.